Arsenic trioxide: an anti cancer missile with multiple warheads

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Arsenic trioxide (ATO) is a validated treatment for acute promyelocytic leukemia (APL).
• ATO's therapeutic potential is increasingly recognized across various cancer types.
• Understanding ATO's molecular mechanisms is crucial for expanding its clinical applications.

Purpose of the Study:

• To review the downstream molecular events in ATO-induced apoptosis.
• To elucidate the roles of pro-apoptotic and anti-apoptotic proteins in ATO's mechanism of action.
• To examine the involvement of p53, cell cycle regulation, and apoptosis-inducing factors (AIF) in ATO-mediated cancer cell death.

Main Methods:

• Literature review focusing on molecular mechanisms of ATO.
• Analysis of studies investigating intrinsic and extrinsic apoptotic pathways.
• Examination of research on p53, cell cycle, and AIF in ATO-treated cancer models.

Main Results:

• ATO triggers both intrinsic and extrinsic apoptotic pathways.
• Modulation of pro-apoptotic and anti-apoptotic proteins is key to ATO's efficacy.
• p53 activation, cell cycle arrest, and AIF contribute to ATO-induced cancer cell death.

Conclusions:

• ATO induces apoptosis through complex molecular pathways involving key regulatory proteins.
• ATO's effects on cell cycle and p53 highlight its potential beyond APL treatment.
• Further research into ATO's mechanisms can optimize its use in diverse oncological settings.